Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

To develop care processes and personalised cancer medicine by new technologies - A validation study of self-testing home-based capillary kit, the True Dose kit

Reference number
Coordinator Region Stockholm - Karolinska Universitetssjukhuset
Funding from Vinnova SEK 1 500 000
Project duration June 2025 - August 2027
Status Ongoing
Venture Medtech4Health innovators
Call Medtech4Health: Implementation of medical technology in healthcare in 2025

Purpose and goal

The aim is to validate a new home-based self-sampling test from True Dose, for therapeutic drug monitoring in patients with non-small cell lung cancer (NSCLC). The goal is to develop a care model that enables individualized dosing and follow-up at home, thereby improving adherence, reducing side effects, and increasing survival.

Expected effects and result

The project is expected to deliver technical and clinical validation of the True Dose kit and identify organizational requirements for implementation. The outcome will support improved treatment adherence, enhanced quality of life for patients, and more efficient healthcare resource use.

Planned approach and implementation

The project is a prospective, open, non-randomized single-center study to validate the True Dose kit for therapeutic drug monitoring in a home setting. It targets NSCLC patients treated with taxanes or ALK inhibitors. The project also evaluates logistical requirements, usability, and acceptance. A total of 40 patients will be included. Data will be collected via eCRF and analyzed using LC-MS/MS.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 14 July 2025

Reference number 2025-00925